CMS Drug Price Negotiation Guidance Updates with Rachel Sachs

This episode is brought to you by Semafor Healthcare.Delivered weekly from David Lim, Semafor Healthcare connects the dots between decisions in government, business, and technology to reveal how they impact the future of healthcare. Each edition will provide the analysis you need to understand and stay ahead of a rapidly changing landscape. Subscribe for free.Health Affairs' Jeff Byers welcomes Rachel Sachs from Washington University in St. Louis and Deputy Editor Chris Fleming back to the pod to discuss CMS' final guidance for the latest round of the Medicare drug price negotiation program. Related Articles:Administration Releases Medicare Drug Price Negotiation Program Final Guidance For 2028 (Health Affairs Forefront)The Role of Combination Drugs in the Medicare Drug Price Negotiation Program (JAMA)Articulating policy options regarding implementation of the Medicare drug price negotiation program’s renegotiation provision (Brookings Institution)Eye on The IRA (Health Affairs) Subscribe to Semafor Healthcare for free.